Boundless Bio (BOLD) Completes Merger, $230M Placement; Stock Falls

Boundless Bio (BOLD) announced on June 23, 2026, the completion of its merger with Serapha Bio and a private placement raising $230 million. Following the announcement, Boundless Bio's stock declined. The financing is intended to advance Boundless Bio's oncology pipeline, specifically its lead product candidate BOLD-100. The merger with Serapha Bio also expands the company's strategic focus to include infectious disease programs. The private placement included participation from several institutional investors. Further details regarding the specific terms of the financing and the merger were not immediately disclosed.